Compare Sanofi SA (SNY) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs NEOS S&P 500 High Income ETF — how do they compare? Sanofi SA trades at $40.13 (market cap $95.18B), while NEOS S&P 500 High Income ETF trades at $54.07 (market cap $12.50B). The key difference: Sanofi SA is far larger — about 7.6× NEOS S&P 500 High Income ETF's market cap, and Sanofi SA pays a 6.01% dividend while NEOS S&P 500 High Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and NEOS S&P 500 High Income ETF for 57 Days on average.
| SNY | SPYI | |
|---|---|---|
Market Cap | $95.18B | $12.50B |
Volume | 2,995,646 | 3,058,962 |
Sector | Health | Income / Options Overlay |
52-Week High | $52.34 | $54.42 |
52-Week Low | $39.51 | $47.98 |
Typical Hold Time | 94 Days | 57 Days |
Enterprise Value | $114.48B | — |
Dividend Yield | 6.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
SPYI trades at $53.995, showing minimal daily movement with a slight 0.03% decline. The technical outlook is bullish based on moving averages, though oscillators remain neutral. Recent news highlights SPYI's role in income-focused portfolios, with coverage discussing both its high distribution yields and potential risks to principal value from covered call strategies.
The outlook for SPYI centers on its income generation appeal amid market volatility, but investors should weigh the trade-off between high yields and potential capital erosion. Key risks include sequence risk in retirement portfolios and the cap on upside during strong bull markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
